Advances in Endometrial Cancer Research
The immune checkpoint inhibitor pembrolizumab (Keytruda) has been approved for treating patients with advanced endometrial cancer that is dMMR or MSI‑H, cannot be removed surgically, and has gotten worse after other treatments.
This sentence demonstrates a recent therapeutic advancement for a specific molecular subtype of endometrial cancer, illustrating how immunotherapy is expanding treatment options for patients with genetically defined tumors.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Endometrial Cancer - PMC
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024